MBK stands firm on offer price for AsiaPharm
The private equity company has no plans to raise its S$0.725 per share offer for the Chinese pharmaceutical firm, but reserves the right to revise the offer price if a competitive situation arises.
Private equity firm MBK Partners is standing firm on its S$0.725 ($0.53) per share offer price for Singapore-listed drug company AsiaPharm Group, according to ABN Amro Bank, which is advising MBK on the deal.MBKÆs offer has been accepted by shareholders who hold a combined 28.53% of the total issued share capital of AsiaPharm, ABN Amro said in an announcement. AsiaPharm shareholders have until March 31 to decide whether to accept MBK's offer, which values the firm at S$357.4 million (…
Sign In to Your Account
Access Exclusive AsianInvestor Content!
Please sign in to your subscription to unlock full access to our premium AI resources.
Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial—no registration fees required. Click the link to get started.
Note: This free trial is a one-time offer.
¬ Haymarket Media Limited. All rights reserved.